Q.  What does NeoStem do? 

A. NeoStem, Inc. ("NeoStem") is a leader in the development and manufacture of cell therapies. NeoStem has a strategic combination of revenues, including that which is derived from the contract manufacturing services performed by Progenitor Cell Therapy, LLC, a NeoStem company. That manufacturing base is one of the few cGMP facilities available for contracting in the burgeoning cell therapy industry, and it is the combination of PCT's core expertise in manufacturing and NeoStem's extensive research capabilities that positions the company as a leader in cell therapy development. Amorcyte, Inc., also a NeoStem company, is developing a cell therapy for the treatment of cardiovascular disease. Amorcyte's lead compound, AMR 001, represents NeoStem's most clinically advanced therapeutic, poised to commence enrollment in a Phase 2 trial for the preservation of heart function after a heart attack.  Athelos Corporation also a NeoStem company is developing a T-cell therapy for a range of autoimmune conditions with their partner Becton-Dickinson.  NeoStem's pre-clinical assets include its VSEL™ Technology platform for regenerative medicine, which NeoStem believes is an endogenous pluripotent non-embryonic cell that has the potential to change the paradigm of cell therapy as we know it today.

Q. What is NeoStem’s relationship with Progenitor Cell Therapy, LLC?

A. NeoStem is a 100% owner of Progentor Cell Therapy, LLC (PCT), and its subsidiary, NeoStem Family Storage, a private cord blood banking business. NeoStem completed the acquisition of PCT on January 19, 2011 and has retained the management team of PCT.

Q. What is NeoStem’s relationship with Amorcyte?

A. Amorcyte is a wholly owned subsidiary of NeoStem.

Q. What is NeoStem’s relationship with Athelos Inc.?

A. Athelos is a Delaware corporation 80% owned by NeoStem through its wholly owned subsidiary, PCT. To further expand and diversify NeoStem’s efforts in cell therapy, the mission of Athelos is to develop regulatory T cells (T-reg) as a therapeutic to treat disorders of the immune system. Through exclusive world-wide licenses, Athelos has secured the rights to a broad patent estate within the T-reg field.

Q.  What is NeoStem’s relationship with Suzhou Erye Pharmaceutical Company Limited?

A. The Company has a 51% controlling  stake in Suzhou Erye. The majority ownership resulted from the Company’s October 2009 acquisition of China Biopharmaceuticals Holding, Inc. (CBH) and Suzhou Erye was CBH’s primary operating subsidiary.

Q.  What is NeoStem’s ticker symbol, exchange and CUSIP

A.  The Company’s common stock is traded under the ticker symbol NBS on NYSE Amex. The CUSIP for the common stock is 640650305.

Q.  How many common shares does NeoStem have outstanding?

A.  94,102,589shares of the Company’s common stock were outstanding as of September 30, 2011.

Q.  What is NeoStem’s fiscal year?

A.  The Company’s fiscal year ends on December 31.

Q.  Who is NeoStem’s IR contact?

A.   
Trout Group
GitangaliJain Ogawa, Vice President
Phone: (646) 378-2949
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

NeoStem, Inc.
Robin Smith, CEO
Phone: (212) 584-4174
E-mail: This e-mail address is being protected from spambots. You need JavaScript enabled to view it

Q.  Who are NeoStem's auditor and corporate legal counsel?

Q.  Who is NeoStem’s transfer agent?

A. Our transfer agent is Continental Stock Transfer & Trust Company (www.continentalstock.com)